Cargando…
Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Some 14% of global prevalence, based on high-income country populations, suffers from migraine. Chronic migraine is very disabling, being characterized by at least 15 headache days per month of which at least 8 days present the features of migraine. Onabotulinumtoxin A, targeting the machinery for e...
Autores principales: | Corasaniti, Maria Tiziana, Bagetta, Giacinto, Nicotera, Pierluigi, Tarsitano, Assunta, Tonin, Paolo, Sandrini, Giorgio, Lawrence, Gary W., Scuteri, Damiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223125/ https://www.ncbi.nlm.nih.gov/pubmed/37235366 http://dx.doi.org/10.3390/toxins15050332 |
Ejemplares similares
-
Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
por: Scuteri, Damiana, et al.
Publicado: (2022) -
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021) -
Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a randomized, double‐blind, placebo‐controlled trial to assess the efficacy of furocoumarin‐free bergamot loaded in a nanotechnology‐based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia
por: Scuteri, Damiana, et al.
Publicado: (2021) -
Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol
por: Scuteri, Damiana, et al.
Publicado: (2022) -
Dementia and COVID-19: A Case Report and Literature Review on Pain Management
por: Scuteri, Damiana, et al.
Publicado: (2022)